-
3 weeks ago | 
publications.ersnet.org | Lauren E. Eggert |Sarah Rhoads |Michael E. Wechsler |Praveen Akuthota
Remission in the context of chronic disease refers to a sustained period during which the signs and symptoms of the disease are reduced or absent. For asthma in particular, the idea that remission is an achievable clinical outcome has gained traction over recent years with the emergence of biologic agents and their demonstrated real-world effectiveness.
-
2 months ago | 
publications.ersnet.org | Neil Martin |Michael E. Wechsler |Christopher E. Brightling
Reply to S. Mailhot-Larouche and co-workers:We thank S. Mailhot-Larouche and co-workers for their interest in our recent publication on clinical response and clinical remission with tezepelumab treatment, reporting results over 2 years from patients with severe, uncontrolled asthma enrolled in the NAVIGATOR and DESTINATION clinical trials [1].
-
Dec 5, 2024 | 
publications.ersnet.org | Michael E. Wechsler |Guy G. Brusselle |J. Christian Virchow |Arnaud Bourdin
IntroductionGlobally, ∼262 million people are affected by asthma [1], resulting in a significant healthcare and economic burden [2]. Asthma is a heterogeneous, chronic lung disease that affects both adults and children [2]. Different underlying disease processes give rise to multiple clinical asthma phenotypes, thereby contributing to the complexity of treatment strategies, particularly because many patients with asthma have overlapping phenotypes (e.g. both eosinophilic and allergic) [3].
-
Sep 26, 2024 | 
erj.ersjournals.com | Michael E. Wechsler |Guy G. Brusselle |J. Christian Virchow |Stephanie Roseti
FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of Interest: A. Versi has nothing to disclose.
-
Sep 20, 2024 | 
healio.com | Victoria Langowska |Kristen Dowd |Michael E. Wechsler
You've successfully added Asthma and Respiratory Disorders to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Safety and tolerability were consistent with benralizumab’s known profile. Benralizumab is currently approved as an add-on treatment for severe eosinophilic asthma.
-
Sep 1, 2024 | 
openres.ersjournals.com | Michael E. Wechsler |J. Michael Wells
IntroductionChronic obstructive pulmonary disease (COPD), a collective term that includes chronic bronchitis and emphysema, has long carried the mantle as a leading cause of death and disability worldwide [1, 2].
-
Jun 24, 2024 | 
healio.com | Victoria Langowska |Kristen Dowd |Sarah Rhoads |Michael E. Wechsler
You've successfully added Asthma and Respiratory Disorders to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Biologic therapies are underutilized in non-white populations. By identifying barriers to specific biologic therapy, more patients could achieve disease control.
-
May 29, 2024 | 
healio.com | Victoria Langowska |Kristen Dowd |Michael E. Wechsler
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Asthmatic patients with insomnia had more frequent exacerbations and poorer asthma control. This group also had more concurrent mood and sleep disorders compared with patients without insomnia.
-
Sep 1, 2023 | 
openres.ersjournals.com | Anthony N. Gerber |Barry J. Make |Michael E. Wechsler |R. Lee Reinhardt
IntroductionVaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) targeting the ancestral (Wuhan-Hu-1/2019) viral spike (S) protein has been broadly effective at limiting infection and severe coronavirus disease 2019 (COVID-19) [1–6]. With respect to SARS-CoV-2 infection, both the humoral and cell-mediated arms of the adaptive response are important for achieving optimal control of COVID-19 [7].
-
Mar 30, 2023 | 
erj.ersjournals.com | Jonathan Corren |Christopher E. Brightling |Michael E. Wechsler |Andrew Menzies-Gow
Thank you for your interest in spreading the word on European Respiratory Society . NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
